DBV Technologies S.A. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: DBV Technologies S.A.
Reporting Period: Fiscal year ended December 31, 2024.
Business Model: Clinical-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) via the Viaskin platform to treat food allergies. The company has no approved products and generates no product revenue.
Key Focus: Advancing Viaskin Peanut for peanut allergy in toddlers (ages 1-3) and children (ages 4-7) in the U.S. and EU.
Key Financial Metrics
| Metric (in thousands USD) | 2024 | 2023 |
|---|---|---|
| Operating Income | $4,151 | $15,728 |
| Research & Development Expenses | $(89,342) | $(60,223) |
| General & Administrative Expenses | $(28,739) | $(29,500) |
| Net Loss | $(113,918) | $(72,726) |
| Cash and Cash Equivalents (Year-End) | $32,456 | $141,367 |
| Net Cash Used in Operating Activities | $(104,474) | $(79,653) |
Note: Operating income consists primarily of French Research Tax Credits (CIR). The company incurred a net loss of $113.9 million in 2024, an increase of 57% from 2023.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses rose 48% to $89.3 million, driven by a $13.4 million increase in external clinical costs for the VITESSE Phase 3 trial and preparatory activities for COMFORT safety studies.
- Decreased Operating Income: Operating income fell 74% to $4.2 million. This was due to a $4.6 million decrease in Research Tax Credits and the termination of the Nestlé Health Science collaboration in late 2023, which eliminated $7.0 million in other operating income (accrual reversals).
- Cash Burn: Cash reserves declined significantly from $141.4 million to $32.5 million, reflecting the increased operational burn rate.
Guidance, Outlook, and Regulatory Status
Regulatory Pathways:
- Toddlers (1-3 years): The FDA has aligned with an Accelerated Approval pathway. The company plans to submit a Biologics License Application (BLA) supported by the completed EPITOPE Phase 3 study and the upcoming COMFORT Toddlers safety study (initiating Q2 2025).
- Children (4-7 years): The VITESSE Phase 3 trial screening was completed in Q3 2024. Topline results are expected in Q4 2025. The FDA agreed that VITESSE safety data will be sufficient for a BLA, eliminating the need for a separate COMFORT Children study. A BLA submission is planned for the first half of 2026.
Capital Resources & Liquidity:
- Post-Period Financing: On April 7, 2025, the company completed a private placement (2025 PIPE) raising $125.5 million in initial net proceeds, with potential additional proceeds of up to $181.4 million upon warrant exercise.
- Cash Runway: Management estimates cash is sufficient to fund operations into June 2026. With full warrant exercise, visibility extends into 2028.
Risks: The company faces significant risks regarding the success of clinical trials, regulatory approval timelines, and the need for additional capital if financing is not available on acceptable terms.
Key Facts for Investor Verification
- Viaskin Peanut Efficacy: Verify the upcoming Q4 2025 topline results of the VITESSE Phase 3 trial (ages 4-7) and the status of the COMFORT Toddlers safety study initiation.
- Capital Adequacy: Confirm the utilization of the $125.5 million raised in April 2025 and the likelihood of exercising the remaining warrants to extend the cash runway beyond mid-2026.
- Regulatory Alignment: Monitor FDA feedback on the Accelerated Approval pathway for toddlers and the specific requirements for the post-marketing confirmatory study.
- Cost Management: Assess the sustainability of the current burn rate (~$104M operating cash outflow in 2024) relative to the new capital raised.